1. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998;134:874–6.10.1001/archderm.134.7.874
3. Descamps V, Ben Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. Prise en charge du drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2010;137:703–8. [In French]10.1016/j.annder.2010.04.024
6. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007;156:1083–4.10.1111/j.1365-2133.2007.07807.x
7. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol 2013;6(6):31–7.
8. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-11.
9. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug ypersensitivity syndrome (Drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.10.1016/S1085-5629(96)80038-1
11. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010;146:1373–9.10.1001/archdermatol.2010.19820713773
13. Halink DA, Marijnissen RM, Schut AA, Oude Voshaar RC. Drug reaction with eosinophilia and systemic symptoms induced by carbamazepine: DRESSed to kill. Gen Hosp Psychiatry 2011;33(4):412.e5–8.10.1016/j.genhosppsych.2011.04.01221762844
14. Tetart F, Picard D, Janela B. Prolonged evolution of drug reaction with eosinophilia and systemic symptoms: clinical, virologic, and biological features. JAMA Dermatol 2014;150:206-7.10.1001/jamadermatol.2013.669824369386
15. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006;155:301-6.10.1111/j.1365-2133.2006.07238.x16882166
16. Tohyama M, Hashimoto K, Yasukawa M. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934-40.10.1111/j.1365-2133.2007.08167.x17854362
17. Um SJ, Lee SK, Kim YH, Kim KH, Son CH, Roh MS, et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol 2010;20:556–62.
19. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu C, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-80.10.1111/bjd.1250123855313
20. Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014;14:281-8.10.1038/tpj.2013.4024322785
21. Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008;47(8):853-60.10.1111/j.1365-4632.2008.03637.x18717872
23. Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009;145(1):63–6.10.1001/archdermatol.2008.521295458819153345
24. Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 2008;23(3):521–5.10.3346/jkms.2008.23.3.521252654018583892
25. Taylor JL, Kulkarni MS, Behringer EC, Yusufali T, Trento A, D’Attellis NP. Minocycline-induced drug reaction with eosinophilia and Systemic symptoms syndrome: myocarditis and multiple organ failure. ICU Dir 2012;3(3):139-43.10.1177/1944451612442687
27. Naisbitt DJ, Farrell J, Wong G, Deptta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393–403.10.1067/mai.2003.150712789244
28. Su-Yin AN, Tai WW, Olson RK. Lamotrigine-associated reversible severe hepatitis: a case report. J Med Toxicol 2008;4(4):258–60.10.1007/BF03161210355011819031378
30. Božić K, Gebauer Bukurov K, Jovanović M, Vujanović Lj, Slankamenac P. Serious rash after prolonged use of lamotrigine - report of four cases. HealthMed 2011;5(2):409-12.
31. Ginory A, Chaney-Catchpole M, Demetree JM, Mayol Sabatier LM, Nguyen M. Drug reaction with eosinophilia and systemic symptoms (DRESS) in an adolescent treated with lamotrigine. J Pediatr Pharmacol Ther 2013;18(3):236–40.10.5863/1551-6776-18.3.236377555824052787
32. Parri N, Bernardini R, Pucci N, Novembre E, Azzari C, Vierucci A. Drug rash with eosinophilia and systemic symptoms induced by lamotrigine therapy. Int J Immunopathol Pharmacol 2007;20:643-5.10.1177/03946320070200032317880778
34. Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A, Belhadjali H, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol 2009;49:1488-91.10.1177/009127000934498519723672
35. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.10.1016/j.amjmed.2011.01.01721592453
38. Brajon D, Trechot P, Waton J, Cuny JF, Schmutz JL, Barbaud A. Suspicion of a new cross-reaction between carbamazepine and olanzapine. J Investig Allergol Clin Immunol 2014;24(1):60-1.
39. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.10.1038/clpt.1981.1547249508